ライフサイエンスコーパス: protective antigen

1 he phenylalanine clamp identified in anthrax protective antigen.

2 at lipopolysaccharide (LPS) is the major OMV protective antigen.

3 o predict the likelihood that a protein is a protective antigen.

4 a major surface antigen of sporozoites, is a protective antigen.

5 s a membrane-anchored glycoprotein and major protective antigen.

6 ce in the lungs and that rPsrP(SRR1-BR) is a protective antigen.

7 GAS esterase and determining whether it is a protective antigen.

8 es and a poor understanding of its role as a protective antigen.

9 ed in sporozoites and EEFs, CS is a dominant protective antigen.

10 sed by furin-dependent processing of anthrax protective antigen.

11 lethal toxin, a mixture of lethal factor and protective antigen.

12 in the endosomal membrane formed by anthrax protective antigen.

13 esses lethal factor and the receptor-binding protective antigen.

14 is considered both a virulence factor and a protective antigen.

15 s a virulence factor, YopE can function as a protective antigen.

16 flagellar proteins are virulence factors and protective antigens.

17 sis system that curates, stores and analyzes protective antigens.

18 ed methods will fail to discover truly novel protective antigens.

19 al polysaccharides are often immunodominant, protective antigens.

20 d the screening and characterization of tick protective antigens.

21 on empirical evidence that these function as protective antigens.

22 e lack of broad-spectrum fungal vaccines and protective antigens.

23 unity to mice was used to identify potential protective antigens.

24 xin (LT) are important virulence factors and protective antigens.

25 t are attenuated yet capable of synthesizing protective antigens.

26 e nucleus for efficient synthesis of encoded protective antigens.

27 dence that fimbrial tip adhesins function as protective antigens.

28 Ad.D4 elicited antibodies to protective antigen 14 days after a single intramuscular

29 ion channel formed by the Bacillus anthracis protective antigen 63 (PA(63)).

30 ctor (LF) and/or Oedema Factor (EF) bound to Protective Antigen 63 (PA63) which functions as both the

31 1lambda monoclonal antibody directed against protective antigen, a component of the anthrax toxin.

32 ne expressing domain 4 of Bacillus anthracis protective antigen, Ad.D4.

33 protein (F1-V) has shown great promise as a protective antigen against aerosol challenge with Y. pes

34 n and thus reveal a paradigm for identifying protective antigens against S. aureus.

35 U2/FP59, composed of the urokinase-activated protective antigen and a fusion protein of Pseudomonas e

36 been well characterized as a surface-exposed protective antigen and a virulence factor of S. pneumoni

37 llus anthracis edema toxin (ET), composed of protective antigen and an adenylate cyclase edema factor

38 emonstrated that detection of the biomarkers protective antigen and capsule correlated with bacterial

39 escence (ECL) immunoassay for the biomarkers protective antigen and capsule.

40 rrA bound to the promoters of genes for both protective antigen and cytochrome aa3, demonstrating tha

41 aracterized the levels of antibodies against protective antigen and found that over half of anthrax v

42 ered recently in Ixodes scapularis as a tick protective antigen and has a role in tick blood digestio

43 vaginal IgA titers against the heterologous protective antigen and higher levels of antigen-specific

44 s to two complex antigens-Bacillus anthracis protective antigen and influenza hemagglutinin-in which

45 ve developed a multiplex biomarker assay for protective antigen and lethal factor of the Bacillus ant

46 These data demonstrate that CFP-10 is a protective antigen and that CFP-10(32-39)-specific CD8+

47 ecific targets, including Bacillus anthracis protective antigen and the enzyme cofactor biotin.

48 ndopeptidase essential for the activation of protective antigen and the formation of anthrax lethal t

49 he increasing structural characterization of protective antigens and epitopes provide the molecular a

50 d T cells that recognize components of these protective antigens and mediate protection.

51 limited by incomplete information regarding protective antigens and the requirement for multiple boo

52 B-type toxins, edema toxin (edema factor and protective antigen) and lethal toxin (lethal factor and

53 antigen) and lethal toxin (lethal factor and protective antigen), and a poly-d-glutamic acid capsule.

54 the genes for anthrax toxins (lethal factor, protective antigen, and edema factor) where expressed 4-

55 Anthrax lethal factor (LF), anti-protective antigen (anti-PA) immunoglobulin G (IgG), and

56 ings are consistent with the ability of anti-protective antigen antibodies to prevent anthrax and sug

57 erage on the liposomes; and immobilized anti-protective antigen antibody concentration.

58 Anti-protective antigen antibody was reported to enhance macr

59 ether, these data demonstrate that different protective antigens are required based on the route of v

60 Protective antigens are specifically targeted by the acq

61 CXO1 encodes pagA1, the homologue of anthrax protective antigen, as well as hasACB, providing for hya

62 vitro and in vivo; it targets the N-terminal protective antigen binding domain.

63 (EF), a key anthrax exotoxin, has an anthrax protective antigen-binding domain (PABD) and a calmoduli

64 and IgG2b variants of the Bacillus anthracis protective antigen-binding IgG1 monoclonal antibody (mAb

65 ial cell surface and is a well-characterized protective antigen but is not essential for virulence.

66 proteins are independent neutralization and protective antigens, but the contribution by F is greate

67 -reactive VHHs block binding of EF/LF to the protective antigen C-terminal binding interface, prevent

68 mposed of phenylalanine (Phe)427 residues of protective antigen catalyses protein translocation via a

69 The protective antigen component of anthrax toxin forms a ho

70 The protective antigen component of Bacillus anthracis toxin

71 sed lethal toxin receptor protein, bound the protective antigen component of lethal toxin, and were s

72 ed on VHHs with in vivo activity against the protective antigen component of the anthrax toxins.

73 tibody fragments engineered to recognize the protective antigen component of the B. anthracis exotoxi

74 abbits and monkeys, the time to detection of protective antigen correlated with the time to bacteremi

75 d GPI-linked parasite protein, Cysteine-rich protective antigen (CyRPA) as an interacting partner of

76 These results provide in vivo evidence of protective antigen-dependent CD8+ T-cell proliferation,

77 al models, treatment with 5H3, a fully human protective antigen-directed monoclonal antibody (PA-MAb)

78 We investigated whether protective antigen-directed monoclonal antibody (PA-mAb)

79 increased mortality (0.8 +/- 0.3, p = .006), protective antigen-directed monoclonal antibody alone re

80 normal saline for 6 hrs or combining it with protective antigen-directed monoclonal antibody followin

81 reatment either alone or in combination with protective antigen-directed monoclonal antibody in a let

82 t significant for all) or when combined with protective antigen-directed monoclonal antibody, so this

83 For example, Protegen stores over 800 protective antigens experimentally proven valid for vacc

84 only 89 and 87% amino acid identity for the protective antigens F and HN, respectively.

85 pleiotropic functions, it is not a dominant, protective antigen for antibody-mediated protection agai

86 examined whether this factor is a potential protective antigen for B. parapertussis.

87 eu5Ac is an essential virulence factor and a protective antigen for GBM, E. coli K1, and P. haemolyti

88 lethal factor, Certhrax was found to require protective antigen for host cell entry.

89 Since the O antigen is a protective antigen for many pathogenic bacteria, we exam

90 ependent surface feature and promising novel protective antigen for preventing P. aeruginosa infectio

91 scape from opsonophagocytic killing and as a protective antigen for S. aureus vaccines.

92 er membrane protein B (rOmpB), constitutes a protective antigen for this group of pathogens.

93 strains, we sought to determine if YopE is a protective antigen for Yersinia pseudotuberculosis and i

94 oteomic analysis as a point of discovery for protective antigens for possible inclusion in a vaccine

95 red for virulence and antigenic may serve as protective antigens for vaccination; thus, five represen

96 Protective antigen forms oligomeric prepores that underg

97 PA63 (the 63-kDa, C-terminal part of protective antigen) forms heptameric channels in cell me

98 ally important activities of its target, the protective antigen from Bacillus anthracis We show how r

99 protein microarray analyses; and (ii) known protective antigens from the literature.

100 oprotein, the viral neutralization and major protective antigen, from an added transcriptional unit.

101 spores with a deletion of the pBCXO1-carried protective antigen gene (pagA1) were severely attenuated

102 The primary cellular receptors for protective antigen have been identified and constructed

103 Presently, 590 protective antigens have been curated against over 100 i

104 While S. aureus protective antigens have been identified in the literatu

105 spores with a deletion of the pBC218-carried protective antigen homologue (pagA2) were not.

106 ly on homology with previously characterized protective antigens; however, homology-based methods wil

107 use toxemia model against recombinant LF and protective antigen, (iii) approximately 50% survival adv

108 ected macrophages against recombinant LF and protective antigen in a cell-based assay, (ii) 100% prot

109 ysaccharide (Ft LPS) is thought to be a main protective antigen in mice and humans, and we have previ

110 romotes influenza virus entry and is the key protective antigen in natural immunity and vaccines.

111 Animals with detectable protective antigen in serum, a significant increase in t

112 simultaneous detection of lethal factor and protective antigen in serum.

113 nt report demonstrates expression of anthrax protective antigen in tobacco chloroplasts--this materia

114 D) and IpaB, have been identified as broadly protective antigens in the mouse lethal pneumonia model.

115 apparatus (T3SA) proteins IpaB and IpaD are protective antigens in the mouse lethal pulmonary model.

116 To appreciate the selection of protective antigens in this model, we sought to characte

117 Protective antigen is not only a vaccine component and t

118 Discovery of novel protective antigens is fundamental to the development of

119 To support data exchange, the information of protective antigens is stored in the Vaccine Ontology (V

120 To confirm that ASP-2 is a protective antigen, laboratory dogs were immunized with

121 We evaluated the ability of the protective antigen, LcrV, and a mutant derivative, V10,

122 The tripartite anthrax toxin consists of protective antigen, lethal factor (LF), and edema factor

123 ed in vitro assembly system, anthrax toxins, protective antigen, lethal factor and their domains, fus

124 ructural genes for the toxin proteins, i.e., protective antigen, lethal factor, and edema factor, dis

125 The Bacillus anthracis secretome includes protective antigen, lethal factor, and edema factor, whi

126 Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is

127 Immunoelectron microscopy with mAbs to protective antigen, lethal factor, edema toxin, and anth

128 ores formed in the endosomal membrane by the protective antigen moiety of anthrax toxin serve as port

129 ores formed in the endosomal membrane by the Protective Antigen moiety of anthrax toxin translocate t

130 assays were used to detect as few as 32,000 protective antigen molecules.

131 hese are both binary-type toxins composed of protective antigen necessary for their cellular uptake a

132 The immobilization of a model ligand, the protective antigen of anthrax on the gold surface, is mo

133 faster immunoglobulin G response against the protective antigen of anthrax than AVA alone.

134 eered for stable plasmid-based expression of protective antigen of anthrax toxin (PA83) fused with th

135 Protective antigen of anthrax toxin forms a pore through

136 to form large pores in the membrane and the protective antigen of anthrax toxin, where a heptameric

137 ata suggest that the O antigen is a critical protective antigen of B. parapertussis and its inclusion

138 gment (scFvs) with increased affinity to the protective antigen of Bacillus anthracis were isolated f

139 ibodies with nanomolar affinities toward the protective antigen of Bacillus anthracis.

140 ot affect the expression of the gene for the protective antigen of the anthrax toxin, pagA, or that o

141 >8)-alpha-Neu5Ac is a virulence factor and a protective antigen of these three pathogens, it is also

142 influenza viruses that bear inserts encoding protective antigens of heterologous viruses can induce a

143 ugh the detection of its polypeptide entity, protective antigen (PA toxin) using a PA toxin ssDNA apt

144 n only the protease-activated 63-kDa form of protective antigen (PA(63)) and the residual 20-kDa frag

145 The action of anthrax toxin begins when the protective antigen (PA(83), 83 kDa) moiety binds to a ma

146 gle-chain variable fragments (scFvs) against protective antigen (PA) and 2 scFvs against lethal facto

147 ively) receptor decoys bind to anthrax toxin protective antigen (PA) and compete with cellular recept

148 Edema toxin, consisting of protective antigen (PA) and edema factor (EF), causes th

149 te anthrax lethal toxin (LeTx) consisting of protective antigen (PA) and lethal factor (LF) is a majo

150 n monoclonal antibodies with specificity for protective antigen (PA) and lethal factor (LF).

151 toxin (LT) is a bipartite toxin composed of protective antigen (PA) and lethal factor (LF).

152 and cell-mediated immune (CMI) responses to protective antigen (PA) and lethal factor were assayed b

153 s composed of the receptor-binding component protective antigen (PA) and of the adenylyl cyclase cata

154 ernatant of Bacillus anthracis, contains the protective antigen (PA) and traces of the lethal and ede

155 f three proteins: the translocase component, protective antigen (PA) and two enzyme components, letha

156 Atx is comprised of three proteins: protective antigen (PA) and two enzymes, lethal factor (

157 use a B-cell epitope from Bacillus anthracis protective antigen (PA) as a model antigen to characteri

158 a) 305 to 319 from the 2beta2-2beta3 loop of protective antigen (PA) can elicit high-titered antibody

159 cellular uptake of complexes containing the protective antigen (PA) carrier of anthrax toxin moietie

160 imals vaccinated with inactivated spores and protective antigen (PA) compared to vaccination with PA

161 acidic endosomal pH conditions, the toxin's protective antigen (PA) component forms a transmembrane

162 Proteolytic activation of the protective antigen (PA) component of anthrax toxin allow

163 The neutralizing antibody response to the protective antigen (PA) component of anthrax toxin elici

164 wn that Lactobacillus gasseri expressing the protective antigen (PA) component of anthrax toxin genet

165 The protective antigen (PA) component of the anthrax toxin (

166 The protective antigen (PA) component of the anthrax toxin f

167 The protective antigen (PA) component of the toxin assembles

168 The role of the protective antigen (PA) component of the toxin is to del

169 toxin is a tripartite toxin comprised of the protective antigen (PA) component, a homooligomeric tran

170 Anthrax toxin protective antigen (PA) delivers its effector proteins i

171 To detect low levels of the anthrax protective antigen (PA) exotoxin in biological fluids, w

172 Protective antigen (PA) from anthrax toxin assembles int

173 In this study, we modified the B. anthracis protective antigen (PA) gene for optimal expression and

174 ith the LT components lethal factor (LF) and protective antigen (PA) individually, or in combination.

175 Bacillus anthracis protective antigen (PA) is an 83-kDa (PA83) protein that

176 Protective antigen (PA) is essential for the action of B

177 man CMG2 receptor and the Bacillus anthracis protective antigen (PA) is essential for the transport o

178 Protective antigen (PA) is the anthrax toxin protein rec

179 Protective antigen (PA) is the cell surface recognition

180 The anthrax protective antigen (PA) is the receptor-binding subunit

181 The protective antigen (PA) moiety of anthrax toxin binds to

182 stry differed in sensitivity mediated by the protective antigen (PA) moiety of anthrax toxin by more

183 The protective antigen (PA) moiety of anthrax toxin forms a

184 The protective antigen (PA) moiety of anthrax toxin forms ol

185 toxin relies in part upon the ability of the protective antigen (PA) moiety to form a heptameric pore

186 pore in the endosomal membrane formed by the protective antigen (PA) moiety.

187 Protective antigen (PA) of anthrax toxin binds cellular

188 n of immune-enhancing cytokine IL-15 and the protective antigen (PA) of B. anthracis into the Wyeth v

189 Cellular immune responses against protective antigen (PA) of Bacillus anthracis in subject

190 ss II tetramers containing peptides from the protective antigen (PA) of Bacillus anthracis to detect

191 3' UTR, regulating expression of the anthrax protective antigen (PA) or human proinsulin (Pins) fused

192 plexes, each containing a heptameric form of protective antigen (PA) plus up to a total of three mole

193 the anthrax bacillus is to determine how the protective antigen (PA) pore mediates translocation of t

194 ion, when these MAbs were mixed with MAbs to protective antigen (PA) previously generated in our labo

195 subprotective dose of a neutralizing MAb to protective antigen (PA) prolonged mean time to death of

196 The protective antigen (PA) protein binds to receptors, eith

197 5 adenovirus (Ad) vector expressing anthrax protective antigen (PA) provides rapid protection agains

198 The absence of capsule or protective antigen (PA) resulted in complete avirulence,

199 tive, specific and easy detection of anthrax protective antigen (PA) toxin in picogram concentration

200 us acidophilus to deliver Bacillus anthracis protective antigen (PA) via specific dendritic cell-targ

201 Large polypeptides of the Bacillus anthracis protective antigen (PA) were inserted into an influenza

202 capsule and two binary toxins, complexes of protective antigen (PA) with lethal factor (LF) and edem

203 er a human monoclonal antibody (AVP-21D9) to protective antigen (PA) would protect mice, guinea pigs,

204 The currently available vaccine is based on protective antigen (PA), a central component of anthrax

205 ancing or neutralizing to Bacillus anthracis protective antigen (PA), a component of anthrax toxin, r

206 Protective antigen (PA), a key component of anthrax toxi

207 is composed of a translocase channel, called protective antigen (PA), and an enzyme, called lethal fa

208 , consisting of the cellular binding moiety, protective antigen (PA), and the catalytic moiety, letha

209 translocase channel-forming subunit, called protective antigen (PA), and two substrate proteins, cal

210 ith AVP-21D9, a human monoclonal antibody to protective antigen (PA), at the time of Bacillus anthrac

211 toxic complexes after one of these proteins, protective antigen (PA), binds to tumor endothelial mark

212 The third, termed Protective Antigen (PA), is a multifunctional protein th

213 Anthrax toxin, comprising three proteins-protective antigen (PA), lethal factor (LF), and edema f

214 The anthrax toxins are three polypeptides-protective antigen (PA), lethal factor (LF), and edema f

215 The toxin is composed of three proteins, protective antigen (PA), lethal factor (LF), and edema f

216 gh degree of metabolic activity and secreted protective antigen (PA), lethal factor, and edema factor

217 plasmid pXO1 that encodes the toxin protein protective antigen (PA), lethal factor, and edema factor

218 x disease is caused by a toxin consisting of protective antigen (PA), lethal factor, and edema factor

219 lf-assembly of its three component proteins--protective antigen (PA), lethal factor, and edema factor

220 Protective antigen (PA), lethal factor, and edema factor

221 illus anthracis edema toxin (ET) consists of protective antigen (PA), necessary for host cell toxin u

222 The toxin's channel-forming component, protective antigen (PA), oligomerizes to create a precha

223 ate protein components: the receptor-binding protective antigen (PA), the adenylyl cyclase edema fact

224 Bacillus anthracis protective antigen (PA), the B subunit of the binary ant

225 Protective antigen (PA), the binding subunit of anthrax

226 iated vasculature and acts as a receptor for Protective Antigen (PA), the cell-binding component of t

227 ies to the immune system in combination with protective antigen (PA), the principal immunogen in AVA,

228 cillus anthracis vaccine consists largely of protective antigen (PA), the protein of anthrax toxin th

229 Protective antigen (PA), the receptor-binding component

230 bipartite toxin in which the first protein, protective antigen (PA), transports the second protein,

231 nto the host-cell cytosol by a third factor, protective antigen (PA), which binds to cellular anthrax

232 nto host cells through interactions with the protective antigen (PA), which binds to host cellular re

233 ty-enhanced monoclonal antibody (ETI-204) to protective antigen (PA), which is the central cell-bindi

234 Current evidence suggests that protective antigen (PA)-based anthrax vaccines may elici

235 genotypes, haplotypes, and homozygosity and protective antigen (PA)-specific cellular immune respons

236 segments derived from the Bacillus anthracis protective antigen (PA).

237 es the binding of the anthrax toxin subunit, protective antigen (PA).

238 the adenylate cyclase edema factor (EF) and protective antigen (PA).

239 rimary protective component is thought to be protective antigen (PA).

240 edema factor (EF) to the pore-forming moiety protective antigen (PA).

241 thal toxin (LT), a complex of LF and anthrax protective antigen (PA).

242 factor (LF) enzymes, and the multifunctional protective antigen (PA).

243 ain, LF(N), to oligomeric forms of activated protective antigen (PA).

244 s lethal factor (LF), edema factor (EF), and protective antigen (PA).

245 ethal factor (LFn), which were used with Atx protective antigen (PA).

246 rearrangement of sub-domains of the exotoxin protective antigen (PA).

247 Anthrax protective antigen (PA, 83 kDa), a pore-forming protein,

248 creted by fully virulent Bacillus anthracis, protective antigen (PA, 83 kDa), lethal factor (LF, 90 k

249 cation pathway and found that binding of the protective-antigen (PA) component of LT to cells and the

250 hrax edema toxin (ET; edema factor [EF] plus protective antigen [PA]) and lethal toxin (LT; lethal fa

251 Single channels of Bacillus anthracis protective antigen, PA(63), were reconstituted into plan

252 into cancer cells using a toxin transporter (Protective antigen, PA) which was redirected to Epiderma

253 that bound and neutralized the pagA1-encoded protective antigen (PA1) but not the PA2 orthologue enco

254 plasmid that encodes the Bacillus anthracis protective antigen (PA63) gene fragment, it was shown th

255 We utilized full-length protective antigen (PA83) of anthrax toxin from Bacillus

256 tro against the fluorescent peptide, anthrax protective antigen (PA83), and influenza hemagglutinin s

257 lethal factor (lef), edema factor (cya), or protective antigen (pagA).

258 of this pathogen have made the discovery of protective antigens particularly difficult.

259 hem, the Plasmodium falciparum Cysteine-Rich Protective Antigen (PfCyRPA) is a crucial component of a

260 Protective antigens play important roles in vaccine deve

261 h direct electron counting, we determine the protective antigen pore structure at 2.9-A resolution.

262 e for CCT in translocation of LF through the protective antigen pore.

263 w that both variants can translocate through protective antigen pore.

264 Although atomic structures of protective antigen prepores are available, how protectiv

265 wcaM)8 mutation resulted in higher levels of protective antigen production during in vitro growth.

266 mid with lux expression under control of the protective antigen promoter displayed luminescence only

267 LcrV of Yersinia pestis is a major protective antigen proposed for inclusion in subunit pla

268 A mAb to protective antigen protected macrophages against vesicle

269 Using ovalbumin and Bacillus anthracis protective antigen protein as model antigens, we showed

270 his sandwich immunoassay, the model analyte, protective antigen protein from B. anthracis, was captur

271 Deletion of protective antigen resulted in greater loss of virulence

272 the expression of a major neutralization and protective antigen, resulting in reduced immunogenicity.

273 Immunization with a recombinant form of the protective antigen (rPA) from Bacillus anthracis has bee

274 mmunized with recombinant Bacillus anthracis protective antigen (rPA) mixed in NE as an adjuvant.

275 The recombinant protective antigen (rPA) of Bacillus anthracis is a prom

276 uginosa exotoxin A, recombinant B. anthracis protective antigen (rPA), and tetanus toxoid (TT).

277 ether spontaneous deamidation of recombinant protective antigen (rPA)--the major component of new-gen

278 ation interface is developed for interactive protective antigen search.

279 otective antigen prepores are available, how protective antigen senses low pH, converts to active por

280 ss of vaccine adjuvants, capable of inducing protective antigen-specific immune responses through nee

281 diphtheria toxin, anthrax lethal factor and protective antigen, Staphylococcus aureus enterotoxin B,

282 idence for a "loop swap" between neighboring protective antigen subunits, which is required for effic

283 a chimpanzee-derived monoclonal antibody to protective antigen that improved survival when administe

284 plague bacterium Yersinia pestis is a potent protective antigen that is under development as a vaccin

285 is of this immunity or the identification of protective antigens that enable vaccine development was

286 xpresses a variety of structurally conserved protective antigens that include cell surface polysaccha

287 This analysis identified protective antigens that, when tested as vaccines in mic

288 tus from structure-based studies of its main protective antigen, the fusion (F) glycoprotein.

289 correlating with serum immunoglobulin G anti-protective antigen titers.

290 creted by Bacillus anthracis, interacts with protective antigen to form a bipartite toxin (lethal tox

291 , the ability of rTP0136 protein to act as a protective antigen to subsequent challenge with infectio

292 e of glucose increased the expression of the protective antigen toxin component-encoding gene (pagA)

293 Hyperimmunization with anthrax protective antigen triggered a hIgG-mediated humoral imm

294 form of the CFA/I fimbrial tip adhesin, is a protective antigen, using a lethal neonatal mouse ETEC c

295 munoassay, a limit of detection of 4.1 ng/mL protective antigen was observed with an upper limit of 5

296 the hypothesis that deletion of gD-2 unmasks protective antigens, we evaluated the efficacy and safet

297 However, when several known protective antigens were deleted, the killed pneumococca

298 challenge with B. melitensis 16M strain, two protective antigens were found: the periplasmic protein,

299 GENpro correctly classifies 82% of the known protective antigens when trained using only the protein

300 Bacillus anthracis infection is a complex of protective antigen, which localizes the toxin to the cel